Is there still a role for aprotinin in cardiac surgery?

Drug Safety

Volumn 30, Issue 9, 2007, Pages 731-740

  Sodha, Neel R ^a   Boodhwani, Munir ^b   Sellke, Frank W ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; APROTININ; CLOPIDOGREL; INOTROPIC AGENT; METHYLPREDNISOLONE; PLACEBO; TRANEXAMIC ACID;

ACUTE CORONARY SYNDROME; BLOOD CLOTTING DISORDER; BLOOD TRANSFUSION; BRAIN PROTECTION; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDEMA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART INFARCTION; HEART PROTECTION; HEART SURGERY; HEMOSTASIS; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOW DRUG DOSE; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VASODILATATION;

APROTININ; CARDIAC SURGICAL PROCEDURES; CEREBROVASCULAR DISORDERS; HEMOSTATICS; HUMANS; MYOCARDIAL INFARCTION; RENAL INSUFFICIENCY; SERINE PROTEINASE INHIBITORS; THROMBOSIS;

EID: 34548303244     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730090-00001     Document Type: Review

References (97)

1. Ramlawi B, Feng J, Mieno S, et al. Indices of apoptosis activation after blood cardioplegia and cardiopulmonary bypass. Circulation 2006; 114 (1 Suppl.): I257-63
2. Saldanha C, Hearse DJ. Cardioplegia and vascular injury: dissociation of the effects of ischemia from those of the cardioplegic solution. J Thorac Cardiovasc Surg 1994; 108: 279-90
3. Anselmi A, Abbate A, Girola F, et al. Myocardial ischemia, stunning, inflammation, and apoptosis during cardiac surgery: a review of evidence. Eur J Cardiothorac Surg 2004; 25: 304-11
4. Biglioli P, Cannata A, Alamanni F, et al. Biological effects of off-pump vs. on-pump coronary artery surgery: focus on inflammation, hemostasis and oxidative stress. Eur J Cardiothorac Surg 2003; 24: 260-9
5. de Vroege R, te Meerman F, Eijsman L, et al. Induction and detection of disturbed homeostasis in cardiopulmonary bypass. Perfusion 2004; 19: 267-76
6. Pintar T, Collard CD. The systemic inflammatory response to cardiopulmonary bypass. Anesthesiol Clin North America 2003; 21: 453-64
7. Mojcik CF, Levy JH. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann Thorac Surg 2001; 71: 745-54
8. Gomes WJ, Erlichman MR, Batista-Filho ML, et al. Vasoplegic syndrome after off-pump coronary artery bypass surgery. Eur J Cardiothorac Surg 2003; 23: 165-9
9. Hazama S, Eishi K, Yamachika S, et al. Inflammatory response after coronary revascularization: off-pump versus on-pump (heparin-coated circuits and poly2methoxyethylacrylate-coated circuits). Ann Thorac Cardiovasc Surg 2004; 10: 90-6
10. Lazar HL, Bao Y, Rivers S. Does off-pump revascularization reduce coronary endothelial dysfunction? J Card Surg 2004; 19: 440-3
11. Aljassim O, Karlsson M, Wiklund L, et al. Inflammatory response and platelet activation after off-pump coronary artery bypass surgery. Scand Cardiovasc J 2006; 40: 43-8
12. Goodnough LT, Brecher ME, Kanter MH, et al. Transfusion medicine. First of two parts: blood transfusion. N Engl J Med 1999; 340: 438-47
13. Moulton MJ, Creswell LL, Mackey ME, et al. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996; 111: 1037-46
14. Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth 2004; 8: 267-81
15. Karkouti K, Wijeysundera DN, Yau TM, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004; 44: 1453-62
16. Spiess BD, Royston D, Levy JH, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004; 44: 1143-8
17. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-65
18. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297: 471-9
19. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion 2006; 46: 327-38
20. Alderman EL, Levy JH, Rich JB, et al. Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg 1998; 116: 716-30
21. Royston D, Bidstrup BP, Taylor KM, et al. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 2: 1289-91
22. Lemmer Jr JH, Stanford W, Bonney SL, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency: a multicenter, randomized, double-blind, placebo-controlled study. J Thorac Cardiovasc Surg 1994; 107: 543-51; discussion 551-3
23. Lemmer Jr JH, Dilling EW, Morton JR, et al. Aprotinin for primary coronary artery bypass grafting: a multicenter trial of three dose regimens. Ann Thorac Surg 1996; 62 (6): 1659-67; discussion 1667-8
24. Levy JH, Pifarre R, Schaff HV, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995; 92 (8): 2236-44
25. Bidstrup BP, Harrison J, Royston D, et al. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993; 55: 971-6
26. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004; 128: 442-8
27. Henry DA, Moxey A, Carless J, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 1999; (4): CD001886
28. Fritz H, Wunderer G. Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. Arzneimittelforschung 1983; 33: 479-94
29. Mahdy AM, Webster NR. Perioperative systemic haemostatic agents. Br J Anaesth 2004; 93: 842-58
30. Khan TA, Bianchi C, Voisine P, et al. Aprotinin inhibits protease-dependent platelet aggregation and thrombosis. Ann Thorac Surg 2005; 79: 1545-50
31. Poullis M, Manning R, Laffan M, et al. The antithrombotic effect of aprotinin: actions mediated via the protease activated receptor 1. J Thorac Cardiovasc Surg 2000; 120: 370-8
32. van Oeveren W, Harder MP, Roozendaal KJ, et al. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990; 99: 788-96; discussion 796-7
33. Coughlin SR, Vu TK, Hung DT, et al. Expression cloning and characterization of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Semin Thromb Hemost 1992; 18: 161-6
34. Coughlin SR, Vu TK, Hung DT, et al. Characterization of a functional thrombin receptor: issues and opportunities. J Clin Invest 1992; 89: 351-5
35. Landis RC, Haskard DO, Taylor KM. New antiinflammatory and platelet-preserving effects of aprotinin. Ann Thorac Surg 2001; 72: S1808-13
36. Ferraris VA, Ferraris SP, Singh A, et al. The platelet thrombin receptor and postoperative bleeding. Ann Thorac Surg 1998; 65: 352-8
37. Day JR, Punjabi PP, Randi AM, et al. Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. Circulation 2004; 110: 2597-600
38. Maquelin KN, Nieuwland R, Lentjes EG, et al. Aprotinin administration in the pericardial cavity does not prevent platelet activation. J Thorac Cardiovasc Surg 2000; 120: 552-7
39. Day JR, Taylor KM, Lidington EA, et al. Aprotinin inhibits proinflammatory activation of endothelial cells by thrombin through the protease-activated receptor 1. J Thorac Cardiovasc Surg 2006; 131: 21-7
40. Sellke FW. Organ protection in cardiac surgery. In: Sellke FW, editor. Improving outcomes in open heart surgery. Boston (MA): Interactive Communications, 2005
41. Poston RS, White C, Gu J, et al. Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. Ann Thorac Surg 2006; 81: 104-10; discussion 110-1
42. Bradfield JF, Bode AP. Aprotinin restores the adhesive capacity of dysfunctional platelets. Thromb Res 2003; 109: 181-8
43. Carr Jr ME, Carr SL, Roa V, et al. Aprotinin counteracts heparin-induced inhibition of platelet contractile force. Thromb Res 2002; 108: 161-8
44. Dietrich W. Reducing thrombin formation during cardiopulmonary bypass: is there a benefit of the additional anticoagulant action of aprotinin? J Cardiovasc Pharmacol 1996; 27 Suppl. 1: S50-7
45. Alston TA. Aprotinin. Int Anesthesiol Clin 2004; 42: 81-91
46. Bidstrup BP, Royston D, Sapsford RN, et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989; 97: 364-72
47. Hongo RH, Ley J, Dick SE, et al. The effect of clopidogrel in combination with aspirin when given before coronary artery bypass grafting. J Am Coll Cardiol 2002; 40: 231-7
48. Akowuah E, Shrivastava V, Jamnadas B, et al. Comparison of two strategies for the management of antiplatelet therapy during urgent surgery. Ann Thorac Surg 2005; 80: 149-52
49. van der Linden J, Lindvall G, Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. Circulation 2005; 112 (9 Suppl.): I276-80
50. Lindvall G, Sartipy U, van der Linden J. Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting. Ann Thorac Surg 2005; 80: 922-7
51. Nader ND, Davidson BA, Tait AR, et al. Serine antiproteinase administration preserves innate superoxide dismutase levels after acid aspiration and hyperoxia but does not decrease lung injury. Anesth Analg 2005; 101: 213-9
52. Erdogan M, Kalaycioglu S, Iriz E. Protective effect of aprotinin against lung damage in patients undergoing CABG surgery. Acta Cardiol 2005; 60: 367-72
53. Ege T, Arar C, Canbaz S, et al. The importance of aprotinin and pentoxifylline in preventing leukocyte sequestration and lung injury caused by protamine at the end of cardiopulmonary bypass surgery. Thorac Cardiovasc Surg 2004; 52: 10-5
54. Lazar HL, Bao Y, Tanzillo L, et al. Aprotinin decreases ischemic damage during coronary revascularization. J Card Surg 2005; 20: 519-23
55. Yun TJ, Rho JR. Aprotinin attenuates the elevation of pulmonary vascular resistance after cardiopulmonary bypass. J Korean Med Sci 2006; 21: 25-9
56. Olivencia-Yurvati AH, Wallace WE, Wallace N, et al. Intraoperative treatment strategy to reduce the incidence of post-cardiopulmonary bypass atrial fibrillation. Perfusion 2002; (17 Suppl.): 35-9
57. Gillespie EL, Gryskiewicz KA, White CM, et al. Effect of aprotinin on the frequency of postoperative atrial fibrillation or flutter. Am J Health Syst Pharm 2005; 62: 1370-4
58. Khan TA, Bianchi C, Voisine P, et al. Reduction of myocardial reperfusion injury by aprotinin after regional ischemia and cardioplegic arrest. J Thorac Cardiovasc Surg 2004; 128: 602-8
59. Bull DA, Maurer J. Aprotinin and preservation of myocardial function after ischemia-reperfusion injury. Ann Thorac Surg 2003; 75: S735-9
60. Karaca P, Konuralp C, Enc Y, et al. Cardioprotective effect of aprotinin on myocardial ischemia/reperfusion injury during cardiopulmonary bypass. Circ J 2006; 70: 1432-6
61. Royston D, Levy JH, Fitch J, et al. Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg 2006; 103: 1082-8
62. Ulker S, Cinar MG, Bayraktutan U, et al. Aprotinin impairs endothelium-dependent relaxation in rat aorta and inhibits nitric oxide release from rat coronary endothelial cells. Cardiovasc Res 2001 Jun; 50 (3): 589-96
63. Fischer JH, Steinhoff M. Effects of aprotinin on endothelium-dependent relaxation of large coronary arteries. Eur J Cardicardiothorac Surg 2005; 28: 801-4
64. Khan TA, Bianchi C, Araujo E, et al. Aprotinin preserves cellular junctions and reduces myocardial edema after regional ischemia and cardioplegic arrest. Circulation 2005; 112 (9 Suppl.): I196-201
65. Wachtfogel YT, Hack CE, Nuijens JH, et al. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am J Physiol 1995 Mar; 268 (3 Pt 2): H1352-7
66. Englberger L, Markart P, Eckstein FS, et al. Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery. Eur J Cardiothorac Surg 2002; 22: 545-51
67. Cugno M, Nussberger J, Biglioli P, et al. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest 2001; 120: 1776-82
68. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993; 106: 1-9; discussion 9-10
69. Hill GE, Alonso A, Spurzem JR, et al. Aprotinin and methyl-prednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 1995; 110: 1658-62
70. Pruefer D, Makowski J, Dahm M, et al. Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion. Ann Thorac Surg 2003; 75: 210-5; discussion 215-6
71. Harmon D, Lan W, Shorten G. The effect of aprotinin on hypoxia-reoxygenation-induced changes in neutrophil and endothelial function. Eur J Anaesthesiol 2004; 21: 973-9
72. Kalangos A, Tayyareci G, Pretre R, et al. Influence of aprotinin on early graft thrombosis in patients undergoing myocardial revascularization. Eur J Cardiothorac Surg 1994; 8: 651-6
73. Havel M, Grabenwoger F, Schneider J, et al. Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994; 107: 807-10
74. Lass M, Welz A, Kochs M, et al. Aprotinin in elective primary bypass surgery: graft patency and clinical efficacy. Eur J Cardiothorac Surg 1995; 9: 206-10
75. Wendel HP, Heller W, Michel J, et al. Lower cardiac troponin T levels in patients undergoing cardiopulmonary bypass and receiving high-dose aprotinin therapy indicate reduction of perioperative myocardial damage. J Thorac Cardiovasc Surg 1995; 109: 1164-72
76. Taggart DP, Djapardy V, Naik M, et al. A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting. J Thorac Cardiovasc Surg 2003; 126: 1087-94
77. Anttila V, Hagino I, Iwata Y, et al. Aprotinin improves cerebral protection: evidence from a survival porcine model. J Thorac Cardiovasc Surg 2006; 132: 948-53
78. Heikkinen J, Kaakinen T, Dahlbacka S, et al. Aprotinin to improve cerebral outcome after hypothermic circulatory arrest: a study in a surviving porcine model. Heart Surg Forum 2006; 9: E719-24
79. Harmon DC, Ghori KG, Eustace NP, et al. Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study. Can Anaesth 2004; 51: 1002-9
80. Buziashvili YI, Ambat'ello SG, Aleksakhina YA, et al. Influence of cardiopulmonary bypass on the state of cognitive functions in patients with ischemic heart disease. Neurosci Behav Physiol 2006; 36: 107-13
81. Buziashvili YI, Aleksakhina YA, Ambat'ello SG, et al. Use of p300 cognitive evoked potentials in the diagnosis of impairments of higher mental functions after cardiac surgery in conditions of cardiopulmonary bypass. Neurosci Behav Physiol 2006; 36: 115-8
82. Levy JH, Sypniewski E. Aprotinin: a pharmacologic overview. Orthopedics 2004; 27: s653-8
83. Asimakopoulos G, Thompson R, Nourshargh S, et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg 2000; 120: 361-9
84. Junge CE, Sugawara T, Mannaioni G, et al. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci U S A 2003; 100: 13019-24
85. Jurk K, Jahn UR, Van Aken H, et al. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost 2004; 91: 334-44
86. D'Ambra MN, Akins CW, Blackstone EH, et al. Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. J Thorac Cardiovasc Surg 1996; 112: 1081-9
87. Feindt PR, Walcher S, Volkmer I, et al. Effects of high-dose aprotinin on renal function in aortocoronary bypass grafting. Ann Thorac Surg 1995; 60: 1076-80
88. Mora Mangano CT, Neville MJ, Hsu PH, et al. Aprotinin, blood loss, and renal dysfunction in deep hypothermic circulatory arrest. Circulation 2001; 104 (12 Suppl. 1): I276-81
89. Fauli A, Gomar C, Campistol JM, et al. Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass. Eur J Anaesthesiol 2005; 22: 666-71
90. Kincaid EH, Ashburn DA, Hoyle JR, et al. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg 2005; 80: 1388-93; discussion 1393
91. Kikura M, Levy JH, Tanaka KA, et al. A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg 2006; 202: 216-22; quiz A44-5
92. Diprose P, Herbertson MJ, O'Shaughnessy D, et al. Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage. Br J Anaesth 2005; 94: 271-8
93. Carless PA, Moxey AJ, Stokes BJ, et al. Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials. BMC Cardiovasc Disord 2005; 5: 19
94. Nuttall GA, Oliver WC, Ereth MH, et al. Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding. Anesthesiology 2000; 92: 674-82
95. Byar DP. Problems with using observational databases to compare treatments. Stat Med 1991; 10: 663-6
96. Hiatt WR. Observational studies of drug safety: aprotinin and the absence of transparency. N Engl J Med 2006; 355: 2171-3
97. Mazer D, Fergusson D, Hebert P, et al. Incidence of massive bleeding in a blinded controlled trial of antifibrinolytic drugs [abstract]. Anesth Analg 2006; 102: SCA1-95